Circulating tumor cells by Next Generation Flow Cytometry as a new prognostic biomarker for patients with asymptomatic monoclonal gammopathies [0.03%]
新一代流式细胞术循环肿瘤细胞作为无症状单克隆丙种球蛋白病患者新的预后生物标志物
Efstathios Kastritis,Panagiotis Malandrakis,Ioannis V Kostopoulos et al.
Efstathios Kastritis et al.
Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study [0.03%]
针对接受抗BCMA/CD3双特异性抗体治疗前的高肿瘤负荷难治复发多发性骨髓瘤患者的去负荷策略：一项回顾性队列研究
Thomas Chalopin,Elise Cellerin,Hélène Demarquette et al.
Thomas Chalopin et al.
Prospective systematic classification of causes of death in the course of multiple myeloma [0.03%]
预期的系统性分类多发性骨髓瘤死亡原因
Jia Xiang Jin,Britta Besemer,Büsranur Yilmaz et al.
Jia Xiang Jin et al.
Chronic inflammatory demyelinating polyneuropathy (CIDP) after cilta-cel therapy [0.03%]
西妥昔单抗治疗后的慢性炎症性脱髓鞘多发神经病(CIDP)
M Korenkov,J Liebaert,S Yousefian et al.
M Korenkov et al.
Ciltacabtagene-autoleucel (cilta-cel) is a CAR-T cell therapy highly active in relapsed/refractory multiple myeloma but can induce severe immune-mediated toxicities. We describe two patients who developed chronic inflammatory demyelinating ...
Prognostic impact of organ involvement in aggressive adult T-cell leukemia/lymphoma: definition of risk organ and proposal of a prognostic index [0.03%]
累及器官对成人T细胞白血病/淋巴瘤预后的意义：风险器官的界定和预后评分系统的建立
Koji Jimbo,Ayumu Ito,Hirona Ichimura et al.
Koji Jimbo et al.
Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression [0.03%]
性别特异性外泌体非编码RNA失调驱动多发性骨髓瘤进展
Samaneh Maleknia,Sanam Rezaei Benam,Greg Ahmann et al.
Samaneh Maleknia et al.
Multiple myeloma (MM) is characterized by the clonal proliferation of plasma cells in the bone marrow. Although the precise molecular mechanisms differentiating men and women in MM are not fully understood, uncovering these differences is c...
Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials [0.03%]
二周期ABVD治疗后正电子发射断层成像/计算机断层扫描（Deauville五分法评分为5分）的晚期经典型霍奇金淋巴瘤患者的疗效分析：三项多中心试验的合并分析
Simonetta Viviani,Chiara Pavoni,Sally F Barrington et al.
Simonetta Viviani et al.
PET after 2 ABVD cycles (PET-2) is widely adopted to select patients with classical Hodgkin lymphoma (cHL), who might benefit from intensifying or de-escalating therapy. Prolonged progression-free survival (PFS) has been reported in PET-2 p...
Multicenter Study
Blood cancer journal. 2025 Oct 16;15(1):165. DOI:10.1038/s41408-025-01364-z 2025
EBV+ polymorphic B-cell lymphoproliferative disorder, NOS: a single-center study of a newly recognized pathologic entity [0.03%]
EBER阳性多形性B细胞淋巴增生性疾病：一种新认识的病理实体的单中心研究
Suheil Albert Atallah-Yunes,Thomas M Habermann,Matthew J Rees et al.
Suheil Albert Atallah-Yunes et al.
EBV-positive polymorphic B-cell lymphoproliferative disorder, NOS (poly B-LPD), is a newly defined entity in the 2022 International Consensus Classification of mature lymphoid neoplasms. Its clinical behavior and optimal treatment approach ...
Equal survival for Black Americans with multiple myeloma when appropriately matched to White Americans [0.03%]
匹配后的黑人和白人多发性骨髓瘤患者具有相同的生存率
David E Mery,Guido Tricot,Samer Al Hadidi et al.
David E Mery et al.
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma [0.03%]
Daratumumab耐药对难治复发多发性骨髓瘤CAR-T治疗临床疗效影响的更正文章
Tara Sebastian,Sridevi Rajeeve,Tasmin Farzana et al.
Tara Sebastian et al.
Published Erratum
Blood cancer journal. 2025 Oct 13;15(1):161. DOI:10.1038/s41408-025-01383-w 2025